Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 16Recruiting 8Completed 3Terminated 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 137Cyclophosphamide 134Paclitaxel 115Carboplatin 108Gemcitabine 98Radiotherapy 84Dexamethasone 83Docetaxel 77atezolizumab 69Ipilimumab 67Fluorouracil 61Doxorubicin 61Blood Specimen Collection 59Bevacizumab 59Rituximab 55fludarabine 54Etoposide 53Oxaliplatin 52Lenalidomide 50Surveys and Questionnaires 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Radiosurgery 44Cetuximab 44lenvatinib 43Capecitabine 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × ceralasertib × 1 year × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03462342 2026-04-13

CAPRI

University of Pennsylvania

Phase 2 Completed
123 enrolled

High Grade Serous Carcinoma

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

AstraZeneca

Phase 2 Completed
54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡